Johnson & Johnson 3Q Revenues: $17.8 billion (+4%) 3Q Earnings: $4.3 billion (+27%) YTD Revenues: $53.8 billion (+3%) YTD Earnings: $12.7 billion (-15%) Comments: Worldwide Pharmaceutical sales were $8.4 billion in the quarter, up 9%. Domestic sales increased 12% and international sales increased 5%. REMICADE sales were $1.8 billion in the quarter, up 11%. STELARA sales were $814 million, up 33%. SIMPONI/SIMPONI ARIA sales were $481 million, up 27%. INVEGA SUSTENNA sales were ...